ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.067,91
-0,31%
S&P 500
5.487,03
0,25%
Dow Jones
38.834,86
0,15%
Euro vs US Dollar
1,07481
0,08%
Bitcoin
64.967,30
0,00%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) News

ARQT Arcutis Biotherapeutics Inc

8,10
0,14 (1,76%)
19 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Arcutis Biotherapeutics Inc ARQT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,14 1,76% 8,10 06:00:05
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
7,90 7,635 8,1653 8,15 7,96
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
18.6.202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.6.202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.6.202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.6.202422:47EDGAR2Form 8-K - Current report
10.6.202420:30GLOBEArcutis Announces New Long-Term Data of Roflumilast Cream..
06.6.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.6.202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
05.6.202414:00GLOBEArcutis Announces Multiple Abstracts, Including Oral..
04.6.202420:03EDGAR2Form 144 - Report of proposed sale of securities
03.6.202414:00GLOBEArcutis to Present at the Goldman Sachs 45th Annual Global..
30.5.202401:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.5.202421:54EDGAR2Form 144 - Report of proposed sale of securities
28.5.202413:00PRNCAArcutis Canada annonce l'acceptation aux fins d'examen par..
20.5.202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202421:58EDGAR2Form 144 - Report of proposed sale of securities
14.5.202422:06EDGAR2Form 8-K - Current report
14.5.202422:00GLOBEArcutis Announces First Quarter 2024 Financial Results and..
14.5.202413:18IHMARKETNEWSUS Futures Remain Steady Amid Wall Street Caution Ahead of..
13.5.202414:00GLOBEExpert Panel Review Further Validates Use of ZORYVE®..
03.5.202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
29.4.202422:00GLOBEArcutis to Report First Quarter 2024 Financial Results..
10.4.202414:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
05.4.202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01.4.202413:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28.3.202413:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11.3.202413:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
10.3.202421:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
09.3.202422:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
06.3.202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
04.3.202423:47EDGAR2Form 144 - Report of proposed sale of securities
04.3.202423:42EDGAR2Form 144 - Report of proposed sale of securities
04.3.202423:40EDGAR2Form 144 - Report of proposed sale of securities
04.3.202422:10EDGAR2Form 8-K - Current report
04.3.202422:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04.3.202414:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
01.3.202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202422:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29.2.202423:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29.2.202405:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
28.2.202422:54EDGAR2Form 144 - Report of proposed sale of securities
28.2.202422:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28.2.202422:10EDGAR2Form 8-K - Current report
28.2.202422:10GLOBEArcutis Announces Proposed Public Offering
28.2.202422:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
27.2.202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202413:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.2.202413:44EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten